✦ LIBER ✦

Etoposide, doxorubicin and cisplatin in advanced or metastatic gastric cancer

✍ Scribed by Merimsky, Ofer; Inbar, Moshe; Chaitchik, Samario

Book ID: 123449370
Publisher: Elsevier Science
Year: 1991
Weight: 132 KB
Volume: 27
Category: Article
ISSN: 0277-5379
DOI: 10.1016/0277-5379(91)90157-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cisplatin, doxorubicin and etoposide (PA

Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: The SAKK experience

✍ A.D. Roth; R. Herrmann; R. Morant; M.M. Borner; H.P. Honegger; R. Obrist; M. Bac 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 47 KB

FLEP (5-fluorouracil, leucovorin, etopos

FLEP (5-fluorouracil, leucovorin, etoposide, cisplatin) in advanced gastric cancer

✍ González-Barón, M.; Feliu, J.; Espinosa, E.; García-Girón, C.; Chacon, I.; Garri 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 277 KB

Pattern of metastatic or local failure a

Pattern of metastatic or local failure after cisplatin + etoposide + doxorubicin (AVP) in small cell lung cancer (SCLC)

✍ Towers, A.G. 📂 Article 📅 1986 🏛 Elsevier Science ⚖ 153 KB

Docetaxel plus cisplatin: active and wel

Docetaxel plus cisplatin: active and well tolerated in locally advanced or metastatic gastric cancer

📂 Article 📅 2001 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

5 Fluorouracil, etoposide, epirubicin, c

5 Fluorouracil, etoposide, epirubicin, cisplatin in treatment of advanced gastric cancer

✍ Bouillet, T; Bloch, P 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Phase II study of a modified combination

Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer

✍ Içli, Fikri; Karaoguz, Handan; Akbulut, Hakan; Dinçol, Dilek; Demirkazik, Ahmet; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB 👁 2 views

## Background: Based on the promising results of eap (etoposide, doxorubicin, and cisplatin) combination, a phase ii study of modified eap combination was performed in patients with advanced gastric cancer to evaluate the response, toxicity, and survival. ## Method: Fifty-two consecutive patients